Beijing, China -- (SBWire) -- 02/09/2011 -- China is the birthplace of Chinese Patent Medicine, and a major producer and consumer of Chinese patent medicine in the world. Driven by both policy incentives and market demand, Chinese patent medicine has developed well in China. From 2006 to 2009, China’s industrial output value and sales revenue of Chinese patent medicine grew at annual rates of 13.9% and 12.7% respectively. The terminal sales revenue of Chinese patent medicine has always accounted for about 30% of the total pharmaceutical revenue of China since 2006. As of August 2010, there had been 1,522 Chinese patent medicine manufacturers in China, including over 30 listed companies, such as Tasly, Tongrentang and Yunnan Baiyao; there had been over 10,000 kinds of Chinese patent medicine, such as Tasly’s Compound Danshen Dripping Pill (Fu Fang Dan Shen Di Wan), Tongrentang’s Bolus of Six Drugs Including Rehmannia (Liu Wei Di Huang Wan) and Bolus of Black-bone Chicken (Wu Ji Bai Feng Wan); there had been over 40 dosage forms, such as traditional bolus, ointment, powder and pellet as well as modern capsule, tablet and spray.

As China’s Chinese patent medicine has gained increasing international recognition and high profit (generally, the operating profit margin is above 70%), and the chemical and pharmaceutical industry has encountered development bottlenecks, global pharmaceutical giants and related institutions have marched into China’s Chinese patent medicine-related fields through joint venture, sole proprietorship or other forms. For example, Novartis and Kunming Pharmaceutical signed a General Agreement on Patent Development Permit for the R & D and production of artemether raw materials, U.S. National Institutes of Health (NIH) (the world's largest medical research institute and research fund management institution) and Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited signed a cooperative agreement on the research of anti-virus mechanism of Baiyunshan Radix Isatidis Granule.

Due to the particularity of Chinese patent medicine market, manufacturers generally can only set foot in some market segments instead of all application fields of Chinese patent medicine. Moreover, as there are a lot of manufacturers engaged in Chinese patent medicine, the competition among them is intense, and the market concentration is low even in market segments. For example, in the field of Chinese patent medicine for cardiovascular and cerebrovascular diseases, top 4 brands accounted for 12.4%, 14.6% and 17.1% of the total market respectively during 2007 to 2009, while top 10 brands held 24.1%, 27.8% and 31.2% of the total market respectively during 2007 to 2009. However, the market concentration of Chinese patent medicine for cardiovascular and cerebrovascular diseases is showing an upward trend in China.

The report analyzes the domestic & global operating environment, current development, supply & demand, competition pattern, import & export and market segments of China’s Chinese patent medicine industry. It also studies the operation and development prospect of 10 listed Chinese patent medicine enterprises, including Tasly, Kanion Pharmaceutical, Yunnan Baiyao, Tibet Cheezheng Tibetan Medicine, Tibet Rhodiola Pharmaceutical, Kunming Pharmaceutical, CONBA, Tongrentang and Guilin Sanjin.

For details of this report please visit http://www.researchinchina.com/Htmls/Report/2010/6022.html

Contact
Helen Wang
ResearchInChina
Tel: 86-10-82600893
Fax: 86-10-82601570
Email: report@researchinchina.com